On August 7, GENSCRIPT BIO rose 6.17% in regular trading, trading at 21.14 HKD/share, with turnover of 788 million HKD, extending recent strong momentum.

On the news front, the company's associate Legend Biotech reported CARVYKTI Q2 trade sales of approximately USD 657 million, up 49.4% year-over-year and 10% quarter-over-quarter. First-half sales reached USD 1.254 billion, representing 55.1% year-over-year growth. Additionally, the company announced a board meeting scheduled for August 15 to review and approve interim results for the six months ended June 30 and consider interim dividend distribution.

The broader CXO sector also provided tailwinds, with WuXi AppTec reporting first-half non-GAAP net profit growth of approximately 89% year-over-year, lifting sector-wide sentiment. Within the Life Sciences Tools and Services sector, WUXI XDC gained 9.39%, PHARMARON rose 8.89%, WUXI BIO added 6.57%, INSILICO climbed 6.25%, and WUXI APPTEC advanced 5.29%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)